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Abstract 
Background 
Risk assessment is central to primary prevention of cardiovascular disease, but there remains 
a need to better understand the use of evidence-based interventions in practice. This study examines: 
a) the policies and guidelines for risk assessment in Europe, b) the use of risk assessment tools in 
clinical practice and c) the barriers to, and facilitators of, risk assessment. 
Methods 
Data were collected from academics, clinicians and policymakers in an online questionnaire 
targeted at experts from all EU member states, and in eight in-depth country case studies that were 
developed from a targeted literature review and 36 interviews. 
Results 
The European Society of Cardiology produces European guidelines for CVD risk assessment 
and recommends the Systematic COronary Risk Evaluation (SCORE) tool, which is the most widely 
used risk assessment tool in Europe. The use of risk assessment tools is variable. Lack of time and 
resources are important barriers. Integrating risk assessment tools into clinical systems and providing 
financial incentives to carry out risk assessments could increase implementation. Novel biomarkers 
would need to be supported by evidence of their clinical effectiveness and cost-effectiveness to be 
introduced in clinical practice. These findings were consistent across Europe. 
Conclusion 
Efforts to improve the assessment of CVD risk in clinical practice should be carried out by, or 
in collaboration with, the European Society of Cardiology. Increasing the use of existing risk 
assessment tools is likely to offer greater gains in primary prevention than the development of novel 
biomarkers. 
Keywords: risk assessment, primary care, primary prevention, cardiovascular disease, health policy 
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Introduction 
Cardiovascular disease (CVD) is the leading cause of death in Europe and accounts for 1.9 
million deaths per year in the European Union (EU).1 In the past 30 years, CVD mortality has 
declined in most countries because of improved survival after coronary events and falling CVD 
prevalence.1-3 Healthier lifestyles, reductions in risk factor prevalence (particularly smoking) and 
pharmacological interventions for high blood pressure and high cholesterol primarily explain these 
improvements.4 
Since the financial crisis, healthcare budgets in Europe have fallen in line with falling tax 
revenue.5 Some health services, such as the NHS in England, have increasingly focused on disease 
prevention to reduce demands on health services and decrease costs.6 Risk assessment remains central 
to primary prevention of CVD. It is carried out to encourage the modification of behavioural risk 
factors,7 guide equitable and cost-effective healthcare delivery and inform clinical decision making.8 
CVD risk assessment may also influence clinicians’ prescribing behaviour.9 
Numerous tools exist to estimate CVD risk.10 The Systematic COronary Risk Evaluation 
(SCORE) tool estimates the 10-year risk of fatal cardiovascular disease.11 Others, such as QRISK212 
and Framingham-based risk scores13, estimate the 10-year risk of experiencing any CVD event. The 
predictive ability of existing tools varies, and novel biochemical and genetic biomarkers to improve 
cardiovascular risk prediction are currently being studied.14  
However, there is often a disconnect between academic research and the use of evidence-
based interventions in practice.15 This study was designed to address that problem in the European 
context. An online questionnaire targeted at experts across Europe and detailed country case studies 
were used to answer three research questions: 1) What policies and guidelines exist for CVD risk 
assessment? 2) How is CVD risk assessment implemented in practice? 3) What are the barriers to, and 
facilitators of, CVD risk assessment, including the use of novel biomarkers? 
Methods 
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Data were collected from academic, clinical and policy experts in all 28 EU member states in 
an online questionnaire and from eight in-depth country case studies. 
Online Questionnaire  
The aim of the questionnaire was to improve our understanding of differences in attitudes 
towards, and policies for, CVD risk assessment in all member states, rather than to provide an 
accurate appraisal of each individual country. Participants were purposively sampled to ensure a range 
of expert views were captured. A scoping literature review of the use of, and guidelines for, CVD risk 
assessment tools in Europe informed the development of the questionnaire. An initial draft was 
circulated to the Public Health Genomics Foundation, the Andalusian School of Public Health in 
Granada and senior academics in health services research. The questionnaire (Supplementary material 
1) was refined on the basis of comments received.  
Referencing the publicly funded healthcare system in their countries, respondents were asked 
to answer questions on guidelines and tools for CVD risk assessment, current use of risk assessment 
tools in clinical practice, barriers and facilitators of risk assessment in general, and specifically, for 
the use and potential uses of novel biochemical and genetic biomarkers. 
The questionnaire was sent to at least one senior stakeholder in CVD prevention at a 
government agency, regulatory agency, professional association, research organisation or patient 
group in every member state. Contacts were identified from national cardiology and hypertension 
societies, European cardiovascular foundations and charities, authors of academic publications on 
CVD prevention and risk assessment (indexed in PubMed) and a small number of additional experts 
that were identified on an ad-hoc basis through the authors’ personal contacts. An initial invitation 
email was sent, with up to three follow-up reminders to non-respondents. Study information was 
provided to invitees at the start of the online questionnaire. The questionnaire was circulated online, in 
English, using Select Survey16 from November 2014 to March 2015.  
Case-studies 
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The eight case studies were selected to reflect variation in: geographical location within 
Europe, health system financing mechanisms, the role of general practitioners (GPs)a as 
“gatekeepers”, the impact of the financial crisis, CVD mortality, the burden of CVD and the cost of 
CVD (Appendix). The case studies were based on interviews and a targeted review of the relevant 
country-specific literature, including documents identified by interviewees and respondents to the 
questionnaire. 
The interviews were semi-structured, including open-ended questions and prompts 
(Supplementary material 2). Interviewees were asked about policies and guidelines for CVD risk 
assessment, barriers and facilitators of risk assessment, current monitoring of biomarkers 
(biochemical and genetic) and potential barriers to the use of more sophisticated CVD risk assessment 
tools. All interviewees gave verbal consent for their interview to be recorded and transcribed and were 
sent a copy of the case study to which their interview contributed.  
Interview participants were identified by the same means as those invited to respond to the 
questionnaire, with the aim of recruiting five interviewees per country, including at least one 
academic, clinical and policy expert. Potential interviewees were sent an invitation email and topic 
guide. The research team carried out the interviews in English, by telephone, between May and 
October 2015. 
Analysis 
Respondents to the questionnaire who only completed the initial question about country of 
residence were excluded from the analysis. Responses to each question were analysed independently 
and non-response was considered on a question-by-question basis. Descriptive statistics by respondent 
and country were calculated and free-text responses were summarised. 
Interview transcripts were coded into organising themes using NVivo17 and emerging findings 
were discussed with the wider study team. Country reports for each case study were developed using a 
                                                          
a Or equivalent primary care doctor in other European countries (e.g. family doctor) 
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narrative synthesis approach based on the interview transcripts, relevant free-text responses to the 
questionnaire and literature review and written using the same template. The eight reports were then 
thematically coded in a cross-country analysis using NVivo.17   
Results 
Participants and respondents 
The questionnaire was sent to 560 experts across Europe. There were 163 responses to the 
first question about availability of guidelines in the respondent’s country. There were 135 responses 
(24% response rate) to at least one subsequent question, with respondents covering all member states 
except Austria. A median of three responses per country was received, ranging from one (Estonia, 
Romania, Slovakia) to 23 (United Kingdom). Respondents were mostly academics (58%) and/or 
clinicians (66%) and a small number were involved in policy (8%) (Supplementary material 3). 
Country case studies included Bulgaria, England, Finland, Germany, Greece, Latvia, Spain 
and Sweden. Thirty-six telephone interviews (3 to 5 per country) were conducted. Each country had at 
least one academic, clinical and policy representative. Table 1 provides a summary of key findings 
from the eight case studies; the full case studies can be accessed online (Supplementary material 4). 
Stakeholders, guidelines, and choice of risk assessment tool 
The majority of national cardiology societies endorse the European Society of Cardiology 
(ESC) prevention guidelines. Questionnaire respondents from most countries reported having national 
guidelines and respondents from two-fifths of countries reported having regional guidelines; although 
respondents from most countries reported that the national and international guidelines were used 
most frequently (Table 2). These findings are consistent with the case studies (Table 1) in that 
interviewees from most countries reported that the ESC is the key organisation in the development of 
European guidelines for the prevention of CVD and that national guidelines for CVD risk assessment 
are often based on the ESC guidelines.  
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We follow the European Society of Cardiology guidelines. Greece is part of Europe so we 
follow these guidelines mainly. [Cardiologist, Academic, Greece] 
Respondents from virtually all countries reported that CVD risk assessment tools are used in 
clinical practice and that the SCORE tool, which is recommended by the ESC, is the most frequently 
used, followed by Framingham-based tools. These findings were consistent across the questionnaire 
and case studies (Table 2). SCORE has been calibrated for high-risk (e.g. Bulgaria and Latvia) and 
low-risk (e.g. Finland) countries, as well as for some individual countries (e.g. Germany, Greece, 
Spain and Sweden). However, the British Society of Cardiology does not endorse the ESC prevention 
guidelines and the National Institute for Health and Care Excellence (NICE) recommends the 
QRISK2 tool.12 There is also regional variation within countries; some regions in Spain recommend a 
Framingham-based tool or the REGICOR (REgistre GIroní del COR, Girona Heart Registry) 
calculator, which is based on a calibrated Framingham model.  
Current use of CVD risk assessment tools in clinical practice 
Responses to the questionnaire suggest that CVD risk assessment tools are widely used by 
doctors in both primary and secondary care; although respondents in just under half of countries also 
reported use by other health professionals, such as practice nurses and pharmacists (Table 2). This 
was supported by the case studies, which found risk assessment to be primarily the responsibility of 
GPs, usually taking place in primary care (Table 1). However, in almost all countries, other health 
professionals also conduct risk assessments (Table 2). Nurses undertake the majority of risk 
assessments for the English NHS Health Check Programme while cardiologists undertake the 
majority of risk assessments in Greece.  
The questionnaire findings suggest that, across Europe, risk assessment is perceived to be 
acceptable to patients and considered of clinical value (Table 2). Interviewees reported that risk 
assessment tools are used in clinical consultations to guide clinical decision-making (e.g. prescribing 
decisions) and encourage lifestyle changes. 
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I have here the SCORE system and the Framingham, and the REGICOR system in my 
computer, so I can easily estimate the risk of my patients with the information that I have in 
their records, but it's not automatically something I can do… I do when I have to make some 
clinical decisions on that specific patient. [GP, Spain] 
Variation in implementation of risk assessment 
The populations targeted for risk assessment vary substantially between countries and 
regions, but are most commonly based on age or medical history. While little data is available on the 
use of risk assessment tools in Europe, the Spanish case study identified two research studies that 
illustrate the variability in the implementation of risk assessment. The first study found that only 36% 
of primary care practitioners surveyed used the Spanish adaptation of the European guidelines and 
only 40% calculated overall cardiovascular risk in more than 80% of their patients with at least one 
risk factor.18 The second study highlighted variable CVD prevention policy across Spanish regions 
and patchy implementation of risk assessment for target populations.19 Interviewees from all countries 
reported that risk assessment use varies between health professionals, practices, and regions.  
Some use it regularly, others don't use it at all, others use it sometimes and they can use 
different tools. [GP, Academic, Germany] 
They attributed the variation to differing attitudes towards prevention and constraints on time and 
resources. In some countries, interviewees also reported mixed views regarding the acceptability of 
risk assessment tools among clinicians (e.g. attitudes regarding clinicians’ roles in primary 
prevention) and scepticism about the effectiveness of risk assessment.  
I worry intensely about how effective it is and whether it’s just people being commissioned to 
provide the service without any real understanding of what that service entails and how to 
change the individual’s cardiovascular risk at the end of it. [GP, Academic, England] 
Interviewees from some countries (e.g. Bulgaria, Latvia, Finland and Sweden) reported that treatment 
and secondary prevention are prioritised over primary prevention.  
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In some parts of the country general practices are not very well resourced and they need to 
concentrate on treating the sick . . . They don’t have or they don’t feel they have had time for 
preventative care. They have their hands full managing the sick patients. [Cardiologist, 
Finland] 
Others reported that risk assessment is often estimated based on individual risk factors, rather than 
using a risk assessment tool.  
The calculation itself is not the best, the most important thing is to be alert, to be alert for 
risks and to give the proper advices and we make the right, take the right decisions and take 
the right actions to prevent and to protect. [GP, Academic, Bulgaria] 
Barriers and facilitators of CVD risk assessment 
The questionnaire found that, for most countries, facilitators of risk assessment in routine 
practice include: guideline recommendations, training, financing, perceptions of importance to 
clinicians and patients, time, and the availability of information technology (Table 3a). These results 
were generally consistent with case study findings; although interviewees emphasised lack of time 
and resources as particularly important barriers. GPs, in particular, reported being overburdened and 
lacking time to conduct risk assessments and follow-up with high-risk patients (Table 1).  
GP’s also have just 15 minutes for every patient and if the patient comes with the other 
problem, there is no time to calculate risk.  [Cardiologist, Latvia]  
Similarly, interviewees in 6 out of 8 case study countries reported shortages or underutilisation of 
nurses to carry out, or assist with, risk assessments (Table 1). 
While respondents to the questionnaire reported that specific payments facilitate risk 
assessment (Table 3a), respondents from less than half of EU countries reported that specific 
payments exist for risk assessment (Table 2). The case studies identified three types of financial 
barriers. At the health system level, interviewees reported a lack of resources for primary prevention 
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and implementation of guidelines. At the clinician level, they reported a lack of reimbursement for 
time spent carrying out risk assessments.  
In some parts of the country general practices are not very well resourced and they need to 
concentrate on treating the sick . . . They don’t have or they don’t feel they have had time for 
preventative care. [Cardiologist, Finland]  
At the patient level, they reported a lack of reimbursement for costs associated with tests and 
treatments (Table 1).  
Yes, but for instance, statins for primary prevention they are not… I think they are not 
reimbursed at all. […] Nowadays statins are reimbursed for secondary prevention actually, 
rather than primary. [Cardiologist, Academic, Bulgaria] 
Interviewees suggested that simpler risk assessment tools that are integrated into electronic 
medical records might save time and increase usage.  
If something was made so that it was integrated with the normal system then it would be 
much, much more likely to be used. [GP, England] 
They also suggested that calibration of tools to specific populations, increased flexibility in the setting 
for risk assessment, and training clinicians to use the tools would increase uptake.  
Novel biochemical and genetic markers of CVD risk 
While some established biomarkers (e.g. cholesterol and blood pressure) are monitored in 
routine clinical practice in most countries, novel biochemical and genetic markers are not routinely 
monitored in any country; they are used only in research. The case studies found that the main barrier 
to the monitoring of biomarkers is the lack of evidence on their clinical and cost effectiveness. 
Interviewees questioned the usefulness of additional biomarkers and reported a need to prove their 
clinical value, improve their sensitivity and/or specificity, prove their cost-effectiveness, and simplify 
their use.  
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Biomarkers have so far not contributed much. We went through biomarkers of different kinds, 
when we wrote the guidelines for management of people with diabetes, prediabetes and 
cardiovascular disease. And we actually couldn't find any strong evidence for any 
biomarkers, and there are many, which actually told us something more than how the patient 
lived. Their blood pressure, their glucose, lipids and so on. So biomarkers are in the general 
perspective, not very useful, not yet. [Cardiologist, Sweden] 
Respondents to the questionnaire from most countries reported that monitoring biomarkers 
would be acceptable to both patients and clinicians (Table 3b) and interviewees generally did not 
foresee challenges regarding acceptability of novel biomarkers among patients and clinicians, 
provided that the conditions outlined above were met.  
Questionnaire respondents reported regulatory and legal concerns associated with the 
monitoring of biomarkers slightly more often for genetic biomarkers compared with biochemical 
biomarkers (Table 3b). However, interviewees did not identify any regulatory or legal issues, even 
when specifically questioned on such issues. 
Oh, well our data protection law is very strong, very severe, so probably, I don't know, but if 
the information is anonymous. You know respecting the individual data protection, that 
shouldn't be any trouble I think. [Cardiologist, Spain] 
Discussion 
This study describes how CVD risk assessment is carried out in practice across Europe. It 
highlights the key role of the ESC, the importance of primary care and variation both within and 
between countries in the implementation of risk assessment. It also confirms the need for reliable 
evidence on the clinical effectiveness and cost effectiveness of new interventions, such as novel 
biomarkers, prior to their introduction into clinical practice.  
The ESC’s first Joint European Guidelines for CVD prevention were published in 1994, and 
with the launch of a strategy in 2002 designed to “reduce cardiovascular deaths by 40%”,20 the 
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organisation has moved from simply providing evidence-based guidelines to influencing European 
cardiovascular risk management policies.20 This study’s findings, such as the widespread use of the 
SCORE tool and the shaping of national guidelines, reflect this broader role. 
We found little published evidence on CVD risk assessment in clinical practice across 
Europe. Consistent with the findings from this study, recent research from the Netherlands highlights 
the gap between positive policy intent and implementation of CVD risk assessment in practice,21 with 
patient, organisation and health system factors all influencing implementation in primary care. A 
systematic review of breast cancer risk prediction models found that the model most widely 
implemented in practice was the one that was most widely available, rather than the model with the 
best predictive ability.22 This is consistent with findings from this research, where it was reported that 
embedding risk prediction into routine electronic patient records is a facilitator of use in practice and 
that the use of the SCORE tool is widespread despite being limited to the prediction of fatal 
cardiovascular events.  
Despite widespread endorsement and acceptance of ESC guidelines, this study identified 
important variations in the implementation of risk assessment, such as the populations targeted and 
variable implementation across health professionals, practices and regions. This variation across and 
within countries was primarily attributed to differing attitudes towards the effectiveness of risk 
assessment and the prioritization of treatment and secondary prevention over primary prevention. 
Such attitudes are likely an important barrier to CVD risk assessment and important for policy makers 
to note, although assessing the pervasiveness of such views was beyond the scope of this study. 
The barriers and facilitators to the implementation of risk assessment identified in this study 
mirror those observed for risk models for type 2 diabetes23 and the implementation of the NHS Health 
Check programme in England.24 Implementation was influenced by the perceived advantages 
(simplicity, ease of use, and predictive ability) and disadvantages (workload, and implications of 
managing a positive score) of the tools. These in turn are affected by factors such as clinicians’ skills, 
influence or endorsement of tools, healthcare system design and external policies, incentives and 
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competing priorities. This study highlighted three levels of financial barriers that would need to be 
addressed to improve the implementation of CVD risk assessment:  resources for primary prevention 
and implementation of guidelines at the health system level; reimbursement for time spent carrying 
out risk assessments at the clinical level; and reimbursement for costs associated with tests and 
treatment at the patient level. These findings suggest that overcoming the financial barriers to risk 
assessment is a key policy area. 
Investigations into the utility of novel factors for the assessment of cardiovascular risk are 
being undertaken. Many studies that have claimed that additional factors could offer further predictive 
value beyond the Framingham algorithm have well-documented flaws.25 Further work employing 
multiple biomarkers has found only limited predictive benefit over conventional risk scores.26 This 
study emphasises the need to demonstrate the predictive value and cost-effectiveness of novel 
biomarkers prior to their implementation. 
The main strength of this research is the inclusion of opinions from academic, clinical and 
policy experts from virtually all EU member states, using a wide-ranging questionnaire and in-depth 
case studies. Although responses are always prone to subjectivity, the expertise of the respondents 
means that the results of this study are likely to reflect practice. Differences in the results between the 
questionnaire and case studies highlight the strength of using different methodologies to gain a clearer 
understanding of opinion.  
However, this study also has important limitations. Identifying stakeholders, academic 
literature and guidelines for some countries was challenging, which could reflect the language barriers 
of the research team or possibly a lack of resources for, or engagement with, cardiovascular risk 
assessment in some countries. Although the response rate was in line with expectations for this type of 
study27,28 and the questionnaire was not intended to be representative of all member states, the 
response rate was nevertheless low and variable across countries, which may be due to the 
questionnaire being written in English or the response burden because of the length of the 
questionnaire. The participation of civil servants and representatives of health ministries and 
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regulatory agencies in the questionnaire was unexpectedly low and thus not fully captured by the 
questionnaire findings; however, policy stakeholders participated in interviews for all of the country 
case studies such that the views of this stakeholder group were included in the analysis. However, we 
also cannot rule out selection bias; it is conceivable that the respondents who viewed the ESC and 
other guidelines most favourably may also have participated in the development of the guidelines. 
Very few stakeholders from CVD charities and patient organisations participated in the questionnaire 
and interviews, despite being invited to participate, such that this research lacks a strong patient voice. 
This study provides valuable insight into CVD risk assessment across Europe, which will 
hopefully act as a useful baseline and provide reference data upon which future studies can draw. The 
ESC has a central role in informing practice in Europe, and efforts to improve CVD prevention are 
likely to benefit from being carried out by, or in collaboration with, the ESC. Although integration of 
risk assessment tools in clinical computer systems may improve uptake, there remain significant 
barriers to the widespread implementation of risk assessment tools, including lack of funding. Despite 
considerable interest in developing novel biomarkers to optimise cardiovascular risk assessment, it is 
likely that focusing efforts on increasing implementation of existing risk assessment tools will offer 
the greatest gains in primary prevention of cardiovascular disease.  
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Keypoints  
• The European Society of Cardiology is important in CVD risk assessment and any changes in 
European risk assessment policy should be made by, or in collaboration with, the ESC. 
• Guideline implementation and use of CVD risk assessment tools in practice is often 
suboptimal. 
• Lack of funding for risk assessment and following up patients identified as at risk is a key 
barrier to widespread implementation of CVD risk assessment in Europe. 
• Novel biochemical and genetic markers of CVD risk are not currently used in routine clinical 
practice; such biomarkers would need to be endorsed in clinical guidelines and shown to be 
both effective and cost-effective in order to be introduced into routine clinical practice in 
Europe.  
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Table 1: Key findings from case-studies 
Case study themes 
Country 
B
u
lg
ar
ia
 
G
er
m
an
y
 
U
K
 
G
re
ec
e 
S
p
ai
n
 
F
in
la
n
d
 
L
at
v
ia
 
S
w
ed
en
 
Policies and guidelines 
ESC prevention guidelines are endorsed X X  X X X X X 
Also have national guidelines  X X X X X X X 
Also have regional guidelines     X   X 
The SCORE risk assessment tool is recommended  X X  X X X X X 
Alternative risk assessment tools in addition to / 
instead of SCORE are also recommended 
  X  X X   
Financial incentive for risk assessment   X    X  
Current practice 
Risk assessment is primarily the responsibility of 
general practitioners and mostly takes places in 
primary care 
X X X  X X X X 
CVD risk assessment is acceptable to patients X X X X X X X  
CVD risk assessment is targeted at specific population 
groups 
X X X X X X X X 
Use of risk assessment is variable between health 
professionals, practices and regions and often is not 
frequently used 
X X X X X X X X 
Risk assessment is often estimated based on risk 
factors rather than formally calculated 
X X X X X    
Treatment and secondary prevention are prioritised X  X   X X X 
There are mixed views regarding the acceptability of 
risk assessment tools for use in practice 
X X X X X X   
Barriers 
Time constraints and clinician workload X X X X X X X X 
Shortage/underutilisation of nurses X   X X X X X 
Funding for risk assessment and follow-up X  X X X  X  
Lack of reimbursement of medicines prescribed for 
primary prevention 
X   X     
Lack of awareness of risk assessment among 
clinicians 
X X  X    X 
Lack of awareness of risk assessment among patients X X      X 
Facilitators 
Simple risk assessment tools  X X X    X 
Incorporation of risk assessment tools into electronic 
medical records 
X  X X X X   
Calibration of risk assessment tools to national 
populations 
 X X      
Flexibility in the setting for risk assessment   X   X  X 
Training for clinicians   X X X   X 
Awareness raising activities X   X X X X  
Novel biochemical and genetic markers 
Novel biomarkers not routinely monitored X X X X X X X X 
Novel biomarkers primarily used in research X     X X X 
Lack of evidence on effectiveness of monitoring novel 
biomarkers 
 X X  X X  X 
24 
 
Likely cost of monitoring novel biomarkers would be 
a barrier 
X X X X X  X  
Novel biomarkers would need to be clinically useful   X X X X  X 
Novel biomarkers would need to improve the 
sensitivity and/or specificity of existing risk 
assessment tools 
X  X X X    
Novel biomarkers would need to be cost-effective X  X X X X  X 
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Table 2. CVD risk assessment across Europe, guidelines and current practice (questionnaire 
findings) 
Question/option (respondents) 
Number 
(%) of 
"Yes" 
responses* 
Number of 
countries 
with at least 
one 
endorsement 
Are CVD guidelines available?   
Any CVD risk assessment guidance (n=158) 143 (90.5) 27/28 
National guidelines (n=163) 124 (76.1) 24/28 
Regional guidelines (n=139) 93 (66.9) 11/27 
Most frequently reported guidelines (where there is more than 
one type of guidance) 
  
International (n=100) 42 (42.0) 18/26 
National (n=100) 53 (53.0) 17/26 
Regional (n=100) 5 (5.0) 4/26 
Are CVD risk assessment tools part of routine clinical practice? 
(n=115) 
90 (78.3) 25/26 
Tools reported as the most widely used by clinicians   
ASSIGN (n=128) 6 (4.7) 2/27 
CUORE (n=128) 11 (8.6) 1/27 
ESH risk chart (n=128) 16 (12.5) 8/27 
FINRISK (n=128) 5 (3.9) 4/27 
Framingham-based calculator (n=128) 38 (29.7) 15/27 
PRECARD (n=128) 0 (0.0) 0/27 
PROCAM (n=128) 4 (3.1) 2/27 
QRISK (n=128) 20 (15.6) 2/27 
Reynolds (n=128) 1 (0.8) 1/27 
RISKARD (n=128) 0 (0.0) 0/27 
SCORE (n=128) 89 (69.5) 26/27 
WHO/ISH (n=128) 3 (2.3) 3/27 
Another tool (n=128) 14 (10.9) 5/27 
Endorsed more than one tool (n=55)   
Who uses CVD risk assessment tools?   
Used by GPs (n=114) 98 (86.0) 26/27 
Used by Specialists in office based practice (n=110) 95 (86.4) 27/27 
Used by Specialists in hospital outpatients (n=106) 92 (86.8) 27/27 
Used by practice nurses (n=97) 27 (27.8) 11/26 
Used by unlicensed nurse assistant/aide (n=90) 8 (8.9) 3/26 
Used by pharmacists (n=98) 22 (22.4) 10/26 
Current practice    
Specific payments for the use (n=113) 22 (19.5) 10/26 
Considered acceptable to patients (n=110) 102 (92.7) 25/26 
Considered important for patients understanding / decision making 
(n=110) 
99 (90.0) 
25/25 
Considered important for healthcare professionals decision making 
(n=108) 
95 (88.0) 
25/26 
Specific consultation time (n=114) 31 (27.2) 13/25 
Training for clinicians (n=112) 64 (57.1) 24/26 
Clinician access to computers (n=124) 
121 
(97.6)** 26/26 
*all responses are reported on a question by question basis 
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** the three "Nos" came from Bulgaria, Spain, Cyprus 
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Table 3a: Current/future facilitators of CVD risk assessment (questionnaire findings) 
 
CVD risk assessment 
Number (%) of 
"Yes" responses 
Number of 
countries with 
any “Yes” 
responses 
Recommendation in guidelines 113/121 (93.4) 26/26 
Specific payment for use 67/112 (59.8) 23/26 
Acceptable to patients 98/108 (90.7) 24/25 
Important for patients understanding / decision making 107/114 (93.9) 25/26 
Important for healthcare professionals decision making 101/109 (92.7) 26/26 
Specific consultation time 69/107 (64.5) 21/26 
Training for clinicians 98/113 (86.7) 24/26 
Clinician access to computers 111/117 (94.9) 26/26 
 
Table 3b: Novel biochemical/genetic biomarkers: future use and regulatory issues 
(questionnaire findings) 
 
"Yes" responses/ 
All responses (%) 
Countries with at 
least one “Yes 
response” 
"Yes" responses/ 
All responses 
(%) 
Countries with at 
least one “Yes 
response” 
 Biochemical Genetic 
Future use 
Concerns about financing in 
routine practice 54/99 (54.5) 21/26 64/96 (66.7) 23/25 
Acceptable to clinicians 105/109 (96.3) 26/26 71/87 (81.6) 24/25 
Acceptable to patients 101/102 (99.0) 26/26 75/84 (89.3) 23/25 
Existing regulatory/legal issues 
Data protection 49/101 (48.5) 20/26 64/98 (65.3) 23/25 
Confidentiality 47/100 (47.0) 18/26 60/95 (63.2) 20/25 
Discrimination 22/89 (24.7) 12/25 29/85 (34.1) 13/24 
Professional negligence 26/77 (33.8) 13/24 28/75 (37.3) 15/24 
Consent 48/94 (51.1) 18/25 66/90 (73.3) 21/25 
 
